Document text
Principal Investigator: Ravi Mangal Patel
Organization: EMORY UNIVERSITY
Fiscal Year: 2024
Award: $344,300
Funding agency: Eunice Kennedy Shriver National Institute of Child Health and Human Development
ABSTRACT
In this renewal application, we highlight the ability, commitment and strengths of Emory University to continue
its more than 3 decades of participation in the Eunice Kennedy Shriver NICHD Multicenter Neonatal Research
Network (NRN). As the largest metropolitan city in the US with a single perinatal-referral center (Emory) and
single academic children's health system (Children's Healthcare of Atlanta-CHOA), we have a large pool of
high-risk admissions. Our center brings together 3 Emory-affiliated Atlanta hospitals: Grady Memorial Hospital,
the largest hospital in Georgia with a focus on caring for underserved populations; Emory University Hospital
Midtown, a high-volume delivery hospital and high-risk maternal center; and CHOA at Egleston, a quaternary
referral center. These sites care for ~8,000 live-births and 1,800 neonatal admissions per year with a single
group of neonatologists from the Pediatric Institute at Emory and CHOA. The inborn extremely preterm infants
and their families comprise populations typically under-enrolled in neonatal trials (87% Black; 3% White) with
diverse sociodemographic characteristics. The Emory center has deep expertise in clinical trials and
epidemiology and a robust infrastructure for clinical research with strong institutional support. Dr. Ravi Patel
will continue to lead the Emory site. He has been NRN PI since 2020 and served as site-PI for 6 randomized
trials since 2012. He has nationally-recognized expertise in neonatal transfusion medicine, necrotizing
enterocolitis, caffeine therapy and perinatal epidemiology. Additionally, Dr. Patel received scientific approval by
the NRN Steering Committee for a randomized trial of platelet transfusion strategies that could be implemented
in the upcoming cycle. Dr. Brenda Poindexter, Chief of the Division of Neonatology, is an established clinical
investigator and internationally renowned researcher in neonatal nutrition. She will continue as alternate PI,
bringing long-standing expertise and service to the NRN as Chair of the Protocol Subcommittee and as NRN
PI for two prior institutions (Indiana University, 2006-2014 and Cincinnati Children's, 2014-2020). Dr. Nathalie
Maitre will continue as follow-up PI, a role she began in 2016. She is a neuroscientist and established follow-up
investigator with unique expertise in the development of quantitative measures of infant neural function. Drs.
Barbara Stoll and Lucky Jain will continue as collaborators, along with a cadre of other talented investigators.
Emory investigators led the two most cited NRN publications in the past decade. Additional strengths include:
1) A consolidated neonatology research infrastructure directed by the PI with 4.5 FTE of coordinators. This
ensures prioritization of NRN studies and the ability to enroll 24/7; 2) Comprehensive follow-up program, with
one of the highest follow-up rates in the NRN and 5 trials with 100% follow-up; 3) Close academic links to the
Marcus Autism center, Emory-Georgia Tech biomedical engineering program, Rollins School of Public Health
and CDC; 4) Strong institutional research strength: Department of Pediatrics ranked #4 in NIH funding; 5)
Broad divisional engagement with the NRN: 10 current faculty have led or served as site-PI for NRN studies.
Terms: <0-11 years old><0-4 weeks old><ASD><Active Follow-up><Address><Admission><Admission activity><Area><Asian><Autism><Autistic Disorder><Biomedical Engineering><Black><Black race><Bleeding><Blood Platelet Transfusion><Blood Platelets><Boston><Bronchopulmonary Dysplasia><Caffeine><Caring><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Cerebral Palsy><Cessation of life><Characteristics><Child><Child Health><Child Youth><Child health care><Childhood><Children (0-21)><Cities><Clinical><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Communicable Diseases><Conduct Clinical Trials><Death><Development><Discipline of obstetrics><Early Infantile Autism><Enrollment><Ensure><Epidemiology><Ethics><Faculty><Family><Funding><Gestation><Gynecology><Health system><Hemorrhage><Hispanic><Hospitals><Hour><Indiana><Individual><Infant><Infantile Autism><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Infrastructure><Institution><International><Intervention><Intervention Strategies><Investigators><Kanner's Syndrome><Lactation><Link><Live Birth><Marrow platelet><Measures><Medicine><Methodology><Mission><Multi-Institutional Clinical Trial><Multi-center Neonatal Research Network><Multi-center clinical trial><Multi-site clinical trial><Multicenter Neonatal Research Network><Multicenter clinical trial><Multisite clinical trial><NICHD><NIH><National Institute of Child Health and Human Development><National Institute of Children's Health and Human Development><National Institutes of Health><Necrotizing Enterocolitis><Neonatal><Neonatal Research Network><Neonatology><Neurophysiology - biologic function><Neurosciences><Newborn Infant><Newborns><Observation research><Observation study><Observational Study><Observational research><Obstetrics><Outcome><Paper><Patients><Perinatal><Perinatal Epidemiology><Peripartum><Persons><Pharmacology><Platelet Transfusion><Platelets><Plts><Population><Pregnancy><Productivity><Protocol><Protocols documentation><Public Health Schools><Publications><Randomization trial><Reproducibility><Research><Research Infrastructure><Research Personnel><Research Support><Research Training><Researchers><Role><Scientific Publication><Services><Site><Talents><Technology><Testing><Thrombocytes><Translating><Underserved Population><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><United States National Institutes of Health><Universities><University Hospitals><Work><active followup><adverse consequence><adverse outcome><autism spectral disorder><autism spectrum disorder><autistic spectrum disorder><bio-engineered><bio-engineers><bioengineering><biological engineering><biomarker development><biomed informatics><biomedical informatics><biomedical referral center><blood loss><child healthcare><chronic lung disease in infants><chronic lung disease in neonatal infants><chronic lung disease in neonates><chronic lung disease in newborns><chronic lung disease in prematurity><chronic lung disease in preterm infants><chronic lung disease of infancy><chronic lung disease of prematurity><clinical epidemiology><clinical infrastructure><cost><develop a vaccine><develop vaccines><development of a vaccine><developmental><enroll><epidemiologic><epidemiological><ethical><experience><extreme prematurity><extremely premature infant><extremely preterm><extremely preterm infant><follow up><follow-up><followed up><followup><high risk><implementation science><improved><infant chronic lung disease><infants with chronic lung disease><innovate><innovation><innovative><interventional strategy><kids><lactating><lactational><maternal risk><metropolitan><neonatal chronic lung disease><neural function><newborn child><newborn children><newborn chronic lung disease><nutrition><participant enrollment><patient enrollment><patient population><pediatric><pediatric care><pediatric department><pediatric health care><pediatric healthcare><post-prematurity respiratory disease><preterm infants with chronic lung disease><programs><protocol development><randomized trial><referral center><research facility><social role><socio-demographics><sociodemographics><success><transfusion medicine><under served group><under served individual><under served people><under served population><underserved group><underserved individual><underserved people><unnecessary treatment><vaccine development><very premature><very preterm><youngster>